|
業務類別
|
-- |
|
業務概覽
|
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales. |
| 公司地址
| Scheelevagen 22, Lund, SWE, 223 63 |
| 電話號碼
| +46 46165670 |
| 傳真號碼
| +46 46127775 |
| 公司網頁
| https://www.hansabiopharma.com |
| 員工數量
| 148 |
| Mr. Evan Ballantyne |
Senior Vice President and Chief Financial Officer |
-- |
21/03/2025 |
| Mr. Soren Tulstrup |
President and Chief Executive Officer |
-- |
21/03/2025 |
|
|
| Dr. Florian Reinaud |
Director |
21/03/2025 |
| Mr. Anders Gersel Pedersen, M.D.,PhD |
Independent Director |
21/03/2025 |
| Mr. Mats Blom |
Independent Director |
21/03/2025 |
| Dr. Hilary Malone |
Independent Director |
21/03/2025 |
| Ms. Eva Nilsagard |
Independent Director |
21/03/2025 |
| Mr. Peter Nicklin |
Chairman of the Board |
21/03/2025 |
| Mr. Jonas Wikstrom |
Independent Director |
21/03/2025 |
|
|
|
|
